Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells

Abstract excerpt

There is a renewed focus on targeted therapy against epigenetic events that are altered during the pathogenesis of lung cancer. However, the use of epigenomic modifiers as monotherapy lacks efficacy; thus, there is a need to develop safe and effective drug combinatorial regimens, which reverse epigenetic modifications and exhibit profound anticancer activity. Based on these perspectives, we evaluated, for the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cholinesterase and Neurodegenerative Diseases
• Share to Enzyme function and inhibition
• Share to Histone Deacetylase Inhibitors Research